Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03938870 · ClinicalTrials.gov registry record
CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease
A clinical trial, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 96
- Enrollment target
NCT03938870: Completed study, sponsored by Washington University School of Medicine.
NCT03938870 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 96 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03938870 has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 96 participants
- Enrollment target
Study Summary
Alzheimer's disease (AD) is the most common cause of dementia and currently has no disease modifying treatments or simple accurate diagnostic tests. The goal of this project is to study how tau (a protein thought to cause AD) is made, transported and cleared in the human body. Better understanding of these processes may lead to improved understanding of AD, earlier diagnosis and a way to evaluate treatment.
Primary Outcome
To measure physiological tau kinetics with the tau SILK method in the CNS of human participants.
Interventions
- OTHER L-Leucine 13C6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2015-08-18 |
| Est. Completion | 2023-07-06 |
What the finished NCT03938870 record still lists
NCT03938870 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 96 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which L-Leucine 13C6 is the first listed.
NCT03938870 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03938870 about?
NCT03938870 is a clinical study titled "CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease". Alzheimer's disease (AD) is the most common cause of dementia and currently has no disease modifying treatments or simple accurate diagnostic tests. The goal of this project is to study how tau (a protein thought to cause AD) is made, transported and cleared in the human body. Better understanding o...
What is the current status of trial NCT03938870?
This trial is currently completed. The enrollment target is 96 participants. The study started on 2015-08-18. Estimated completion is 2023-07-06.
What interventions are being tested in trial NCT03938870?
The interventions under investigation include: L-Leucine 13C6 (OTHER).
Who is sponsoring clinical trial NCT03938870?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI